Kornimate/medical-research-clean huggingface dataset:
effectiveness of neurodynamic techniques for the treatment of carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: carpal tunnel syndrome cts is the most common peripheral neuropathy seen in clinic. it results in marked functional limitations of patients. most patients undergo surgical release which places a heavy burden on health system. neurodynamic exercise is claimed to be an effective physiotherapy treatment for these patients. it is a practical and complications-free treatment which can be used as a home exercise program. this study aims to investigate the effect of median nerve gliding exercise on symptoms severity and functional limitation in cts patients.

* design: two groups randomized controlled trial * participants: 50 subjects diagnosed with cts will be recruited from juh physical medicine and rehabilitation department, diagnosis will be confirmed by a physician clinically and using nerve conduction test. subjects will be randomized into treatment and control groups. * procedures: participants will be recruited from the physical medicine department at juh and the diagnosis and initial assessment will be performed by a physician. baseline outcomes will be measured by an experienced physiotherapist. treatment group: neurodynamics evaluation and treatment will be provided by an experienced physiotherapist. each treatment session involves both manual therapy and median nerve mobilization exercise following the neurodynamics concept. four 60 minutes sessions over a period of four weeks will be performed for each patient. median nerve mobilization exercise will be continued as home exercise program and will be monitored by the treating physiotherapist using exercise diary. control group: four sessions of exercise will be given to participants. cts standard exercise brochure will be given for the patients to follow over 4 weeks. the brochure will include wrist joint strengthening, stretching and arom exercise. outcomes will be measured at the end of the 4 weeks treatment, 6 weeks and 6 months post treatment. • data analysis: microsoft excel and spss will be used for data entry and analysis. descriptive analysis: all obtained data will be tabulated, means, standard deviations and differences will be measured. inferential analysis: two way repeated measure anova will be used to measure differences between the groups.

Eligibility criteria:
inclusion criteria: confirmed cts diagnosis exclusion criteria: previous trauma or surgery involving the upper extremities known neurological condition pregnancy history of radiating neck or back pain in the previous 3 months

Keywords: carpal tunnel syndrome neurodynamics median nerve gliding exercise
safety and efficacy of zoledronic acid in patients with breast cancer with metastatic bone lesions

Conditions: Breast Cancer With Bone Metastasis

Summary: the objective of this study is to assess the clinical benefit of two different dosing schedules of zoledronic acid in patients with metastatic bone lesions from breast cancer who have already been treated with zoledronic acid for about one year.


Eligibility criteria:
inclusion criteria: * female patients ≥ 18 years of age. * written informed consent given. * histologically confirmed stage iv breast cancer with at least one bone metastasis radiologically confirmed. * previous treatment with zoledronic acid every 3-4 weeks, for 9-12 infusions over no more than 15 months. * eastern cooperative oncology group (ecog) performance status ≤2 . * life expectancy ≥ 1 year. exclusion criteria: * more than 3 months since last infusion of zoledronic acid (zometa®). * treatments with other bisphosphonate than zoledronic acid (zometa®) at any time prior to study entry. * serum creatinine \> 3 mg/dl (265 μmol/l) or calculated (cockcroft-gault formula) creatinine clearance (clcr) \< 30 ml/min crcl = ({\[140-age (years)\] x weight(kg)}/ \[72 x serum creatinine (mg/dl)\])x 0.85 * corrected (adjusted for serum albumin) serum calcium \ 12 mg/dl ( 3.0 mmol/l). * current active dental problem including infection of the teeth or jawbone (maxilla or mandibular); dental or fixture trauma, or a recurrent or prior diagnosis of osteonecrosis of the jaw (onj), of exposed bone in the mouth, or of slow healing after dental procedures. * recent (within 6 weeks) or planned dental or jaw surgery (e.g. extraction, implants). * pregnant patients (with a positive pregnancy test prior to study entry) or lactating patients. women of childbearing potential not using effective methods of birth control (e.g. abstinence, oral contraceptives or implants, iud, vaginal diaphragm or sponge, or condom with spermicide). * history of non-compliance to medical regimens or potential unreliable behavior. * known sensitivity to study drug(s) or class of study drug(s). * patients with severe medical condition(s) that in the view of the investigator prohibits participation in the study * use of any other investigational agent in the last 30 days.

Keywords: breast cancer zoledronic acid skeletal related events (sre)
influence of epidural analgesia on natural killer cell (nk) activity after colonic cancer surgery

Conditions: Colonic Neoplasms

Summary: regional anesthesia may decrease the release of endogenous opioids, increase natural killer cell (nk) function and decrease development of metastasis. the recent analysis of the cancer registry has noted an improved 5-year survival in patients who received epidural analgesia during surgery for colorectal carcinoma.


Eligibility criteria:
inclusion criteria: * patients undergoing colonic cancer surgery exclusion criteria: * patients with poor physical status patients needed emergency surgery coagulopathic disorders with international normalized ratio (inr) level more than 1.4 thrombocytopenia with platelets count less 100000 per mcl allergic reaction to local anesthetics in patient history failure to performing the epidural analgesia from another cause preoperative immunomodulating treatment recent history of chemotherapy or radiation therapy

Keywords: epidural analgesia natural killer cells
evaluation of safety and immunogenicity of combined immunization of sipv, dtap and hepa

Conditions: Vaccination

Summary: eligible,healthy infants who have finished the 3-dose-schedule of sipv+dtap combined vaccination clinical trial (nct04053010) will be recruited and divided into 4 groups, and will receive vaccination at the age of 18-month-old as follows: 1. group 1: sipv + dtap + hepa, 2. group 2: sipv only, 3. group 3: dtap only, 4. group 4: hepa only. the immunogenicity and safety of the 4 groups will be compared and analyzed before and 30-40 days after vaccination.

following the clinical trial of "combined immunization of sipv and dtap" in 2019, this study recruits 600 18-month-old subjects who have received 3 doses of sipv + dtap, and gives them a 4th dose of vaccination (booster immunization). they are divided into 4 different groups, with 150 subjects in each group, and are innoculated with different vaccines. to be specific, group 1 receives sipv (0.5ml)+ dtap (0.5ml)+ hepa(0.5ml); group 2 receives sipv (0.5ml); group 3 receives dtap (0.5ml); group 4 receives hepa (0.5ml). blood samples will be collected before vaccination and 30-40 days after this booster immunization. neutralization antibody will be detected to evaluate the seroprotection rates and antibody geometric mean concentrations. the safety of both immunization schedule will be monitored as well.

Eligibility criteria:
inclusion criteria: * subjects must have participated the clinical trial titled "clinic trial to evaluate the safety and immunogenicity of combined immunization of sipv and dtap" (nct04053010) in 2019, and have finished 3 doses of combined immunization of sipv and dtap; * subjects aged 18-19 months old at the date of recruitment; * with informed consent form (icf) signed by parent(s) or guardian(s); * parent(s) or guardian(s) are able to attend all planned clinical appointments and obey/follow all study instructions; * subjects have not been vaccinated with sipv/dtap/hepa at the age of 18-month-old yet; * no less than 14 days since the last dose of vaccination; * axillary temperature ≤37.0℃. exclusion criteria: * with a medical history with hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness; * allergic to any ingredient of vaccine or with allergy history to any vaccine; * subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by hiv), or subjects are in the process of immunosuppressor therapy(taking orally injecting of steroid hormone); * administration of immunoglobulins within 30 days prior to this study; * acute febrile disease(temperature ≥ 37.0°c) or infectious disease; * with a clearly diagnosed history of thrombocytopenia or other coagulopathy, may cause contraindications for subcutaneous injection; * with any serious chronic illness, acute infectious diseases, or respiratory diseases; * with severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications; * with any kind of infectious, purulent, or allergic skin diseases; * with any other factor that makes the investigator determines the subject is unsuitable for this study.
therapeutic drug monitoring of fluconazole in critically ill patients

Conditions: Critically Ill Patients

Summary: this prospective study will research the exposure and its variability to fluconazole after longitudinal administration in critically ill patients

an open label, monocenter pharmacokinetic study will be carried out in critically ill patients, admitted at the university hospitals leuven, receiving multiple dose treatment with fluconazole. the exposure to fluconazole in the icu cohort over multiple days of treatment will be documented. moreover, variability and the correlating covariates that can influence the fluconazole concentration, will be determined.

Eligibility criteria:
inclusion criteria: * \> 18 years * treatment with fluconazole * admitted to an icu ward exclusion criteria: * \< 18 years * dnr 2 or 3

Keywords: pharmacokinetics fluconazole variability target attainment
combination treatment with green tea extract and statins in patients with hypercholesterolemia

Conditions: Hypercholesterolemia

Summary: there is a positive correlation between serum's cholesterol levels and death from cardiovascular disease, especially coronary artery disease. the reduction of plasma lipids levels is one of the main goals of prevention. research has shown that green tea has beneficial effects on health due to the polyphenolic substances (catechins) that it contains. studies have shown that prolonged consumption of polyphenols has a positive effect on factors related to cardiovascular risk such as obesity, dislipidemia and various indicators of oxidative stress. the aim of this study was to examine the possible effects of catechin supplementation, in combination with the classic treatment for the reduction of hypercholesterolemia, statin therapy, on the treatment's effectiveness and in the reduction of classic side effects.

this is a randomized, double - blind placebo controlled trial. the patients will be divided randomly in two groups; one group will receive statin and catechin, while the other statin and placebo for 12 weeks. the experimental group will receive 20 mg atorvastatin (lipitor) daily and 600 mg of catechin in capsules, while the control group will receive 20 mg atorvastatin (lipitor) and placebo in identical capsules of 600 mg for the same time period. the patients will undergo biochemical evaluation in which the serum lipids, the levels of oxidative stress and the antioxidant capacity will be assessed. body composition will be calculated with anthropometric measurements, while the levels of visceral fat, the subcutaneous fat, as well as the level of liver fat infiltration will be examined with the use of computed tomography images. factors related to the patients' quality of life will be assessed by a series of questionnaires. the investigators hypothesized that the combination treatment with statin and green tea extract (catechins)will improve in a greater extent the lipidemic profile, increase antioxidant capacity, reducing significantly visceral fat and intrahepatic lipids content.

Eligibility criteria:
inclusion criteria: * total cholesterol \>200mg/dl, or ldl \>160 mg/dl exclusion criteria: * normal lipidemic profile, on statin medication, diabetes mellitus, liver disease, severe hypertension, pregnancy, or severe side effects after 4 weeks of treatment

Keywords: green tea extract catechins statin atorvastatin body composition visceral fat steatosis oxidative stress quality of life ogtt ogis isi matsuda
hip arthroscopy versus total hip arthroplasty rct

Conditions: Hip Osteoarthritis

Summary: the aim of the proposed study is to perform a comparative pilot, randomized controlled trial of hip arthroscopy versus definitive total hip arthroplasty (tha) for the treatment of early hip osteoarthritis (tönnis grade 1-2) in patients between the ages of 40-60 years.

the purpose of this study is to conduct a randomized trial to compare hip arthroscopy to thr and estimate the long-term cost-effectiveness. specifically, we aim to: 1. estimate the magnitude of the between-groups difference in the primary outcome (hip dysfunction and osteoarthritis outcome score - hoos); 2. evaluate the clinical and cost-effectiveness of early definitive tha compared to arthroscopy for early-stage hip oa at 1-year postoperative; 3. estimate the lifetime cost-effectiveness of arthroscopy vs tha using a markov model; and 4. identify imaging and biomechanical predictors of outcomes following hip arthroscopy

Eligibility criteria:
inclusion criteria: 1. between the ages of 40-60 years at the time of surgery. 2. radiographic evidence of mild to moderate hip oa (tönnis gr 0 with mri chondral wear, tönnis gr 1 and 2). 3. patients must have completed ≥3 months of non-operative management with ongoing symptoms. exclusion criteria: 1. advanced oa, defined as \<2 mm joint space (tönnis gr 3) or those with acetabular or femoral head cysts. 2. patients who are pregnant or may become pregnant around the time of surgery. 3. prior arthroplasty of the contralateral hip. 4. current or prior hip dysplasia (defined by a lateral centre edge angle of \<20 degrees). 5. acetabular protrusio or coxa profunda, making arthroscopic access unsafe/unfeasible.

Keywords: hip scope total hip replacement
ophtalmological characteristics of patients with craniosynostosis followed at the amiens university hospital

Conditions: Craniosynostosis; Strabismus; Intracranial Hypertension; Amblyopia

Summary: craniosynostosis are cranial deformations due to the premature closure of one or more cranial sutures. these deformations affect approximately one in 2.500 births. in the vast majority of cases, craniosynostoses are isolated (non-syndromic) and their origin is not always known. on the other hand, 20% of these deformations are said to be syndromic. craniosynostosis has morphological (associated dysmorphism) and functional (growth conflict between the skull and the brain) repercussions. ophthalmological disorders are frequent: refractive disorders, oculomotor disorders, optic nerve damage, sensory damage. this study aims to describe the ophthalmological clinical characteristics associated with craniosynostosis in patients followed at the amiens university hospital. this is a retrospective study based on the analysis of patient records followed in our center.


Eligibility criteria:
inclusion criteria: * diagnosis of craniostenosis exclusion criteria: * posterior plagiocephalia

Keywords: craniosynostosis strabismus , intracranial hypertension amblyopia
efficacy of changing to travatan® from prior therapy

Conditions: Open-Angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study was to assess the efficacy and tolerability of travatan® solution without benzalkonium chloride (bak) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ocular hypertension or open-angle glaucoma in at least one eye. * be on either latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy (including bak-containing generics) for at least four weeks prior to screening visit. * would benefit from a switch to travatan® solution without bak containing polyquad® preservative due to tolerability issues, in the opinion of the investigator. * iop considered to be safe (in the opinion of the investigator), in both eyes, in such a way that assured clinical stability of vision and the optic nerve throughout the study period. * willing to discontinue the use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study. * best corrected snellen visual acuity of 6/60 (20/200, 1.0 logmar) or better in each eye * other protocol-defined inclusion criteria may apply. exclusion criteria: * known medical history of allergy, hypersensitivity, or poor tolerance to any component of the preparations to be used in this study deemed clinically significant in the opinion of the principal investigator. * any abnormality preventing reliable applanation tonometry in either eye. * severe dry eye or related which has been or currently is being treated with the use of punctal plugs, punctal cautery, restasis®, or topical ocular corticosteroids. * any clinically significant, serious, or severe medical condition. * intraocular conventional surgery or laser surgery in either eye less than three months prior to screening visit. * risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment. * progressive retinal or optic nerve disease from any cause. * women who are pregnant, lactating. * women not using reliable means of birth control. * use of any systemic medication known to affect iop which has not been on stable course for at least 7 days prior to screening visit. * any clinically significant, serious, or severe medical condition. * participation in any other investigational study within 30 days of screening visit. * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma oag oht
a study of the effectiveness and clinical practice use of glecaprevir/pibrentasvir in adolescents with chronic hepatitis c genotypes 1 to 6 in russian federation

Conditions: Hepatitis C Virus (HCV)

Summary: the objective of this study is to assess the effectiveness of the glecaprevir/pibrentasvir (gle/pib) regimen in adolescent participants aged 12 to \<18 years of age with chronic hepatitis c (chc) in clinical practice in the russian federation. the study also plans to assess effectiveness of gle/pib in subpopulations of interest like co-infected hepatitis c virus (hcv)/human immunodeficiency virus (hiv) adolescents, in various hcv genotype/subgenotype, cirrhotic and non-cirrhotic participants, treatment-experienced (prior treatment with pegylated interferon (pegifn) or ifn, and/or ribavirin (rbv) and/or sofosbuvir \[prs\]) and treatment-naïve, adolescents who use drugs (pwud) and non-drug users.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of chronic hepatitis c (chc) with genotypes 1, 2, 3, 4, 5 or 6 with or without compensated cirrhosis * treatment naive or treatment experienced participants * receiving combination therapy with the all oral gle/pib regimen according to standard of care, international guidelines with the current local label * participant and his/her legal representative voluntarily signs and dates an informed consent form * must not be participating or intending to participant in a concurrent interventional therapeutic trial exclusion criteria: none

Keywords: hepatitis c virus (hcv) chronic hepatitis c (c) maviret
quality of life and cardiometabolic risk factors in patients after debanding

Conditions: Bariatric Patients

Summary: follow up of debanding patients

follow up of debanding patients regarding cardiometabolic risk factors

Eligibility criteria:
inclusion criteria: * previous debanding after lap. gastric bypass exclusion criteria: * further bariatric procedures
stimulus-stimulus pairing study

Conditions: Autism Spectrum Disorder

Summary: the purpose of the current study is to deliver the ssp procedure to children diagnosed with autism that do not have vocal language. the study will also aim to gather data in the natural environment using a voice recorder.

the purpose of this study is to teach children with autism who do not produce sounds or words to vocalize sounds or words by using the stimulus-stimulus pairing (ssp) procedure. the investigators will use ssp, an intervention based in behavior analysis, to try to help the child vocalize sounds. a vocal recorder will also be sent home so that the caregiver can record the child's vocalization at home. the caregiver will then be asked to return this so that the investigators can listen to it. by doing this, the investigators hope to learn if the treatment helps increase the child's vocalizations at home. some children in the study will receive treatment immediately. some children may enroll in the study now but not receive intervention until a later date. all children in the study will receive treatment within one year of enrolling in the study.

Eligibility criteria:
inclusion criteria: 1. diagnosis of autism 2. currently do not emit vocalizations or minimally verbal 3. willingness of the participant's parent/guardian to bring their child to the marcus autism center for one-hour appointments, five days a week, for six weeks. exclusion criteria: 1. children with significant problem behavior that interferes with structured intervention

Keywords: stimulus-stimulus pairing